LUPIN — A DECADE-LONG CEILING RECLAIMED AND A P/E AT HALF MEDIANLupin LimitedNSE:LUPINJahirSLUPIN — A DECADE-LONG CEILING RECLAIMED, AND A P/E AT HALF ITS OWN MEDIAN Lupin peaked near 2,120 in 2015 and then spent nine years below it. The decline was brutal — down to roughly 560 by 2020, a failed recovery to 1,250, and back to about 575 in 2022 alongside a genuine operational collapse: an operating margin of 1.3% and a net loss of Rs 1,528 Cr in FY22. That ceiling has now been reclaimed. Price broke the 2,000-2,120 band, retested it through 2025 and held, and made a new high near 2,520-2,550 in 2026. A nine-year ceiling that becomes a defended floor is the strongest structural statement a weekly chart makes, and this one has already passed its retest. The difference between this and most breakout charts is that the fundamentals arrived first. Operating margin has gone 1.3% > 10% > 19% > 23% > 29% > 32% TTM. EPS has gone from -33.62 to 120.98. This is not a chart hoping for a story. The story already printed. The catch is location. At 2,363.5 price sits near the highs, and this week opened at 2,435, printed 2,440, and closed at 2,363.5 — down 2.13% and near the low of its range. That is a rejection, not an entry. STRUCTURE I'M WATCHING Measured objective .. 2,880 – 2,950 . Range projection above the 2,440 shelf. Blue sky above the ATH. All-time high ....... 2,520 – 2,550 . The 2026 high. Reclaiming it opens the measured move. Resistance 1 ........ 2,440 ........ The 2025 spike high. Rejected this week. Current ............. 2,363.5 ...... Upper range. Poor risk/reward from here. Support 1 ........... 2,120 ........ Top of the reclaimed band. Where it gets interesting. Breakout band ....... 2,000 – 2,120 . The 2015 all-time high. Reclaimed, retested, held. Invalidation ........ below 1,980 .. Band failure. The structural case ends here. Deeper support ...... 1,700 – 1,800 . The 2024 consolidation. From 2,363 with invalidation at 1,980, risk is roughly 16% for about 8% to the all-time high. Worse than 1:1. From 2,120 the same stop is roughly 6.6% risk for 20% to the high and far more on a breakout — closer to 3:1. The band is the trade. WHAT THE CHART IS TELLING ME - The retest already happened and it held. Most decade-long breakouts fail their first retest. This one spent 2025 inside the 2,000-2,120 band and came out the top. That is the single most constructive fact on the chart. - New highs on a nine-year base mean no overhead supply. Above 2,550 there is nobody trapped. Moves in that air tend to be fast. - This week is a rejection at 2,440. Open near the high, close near the low. Momentum is pausing, not accelerating. - The trend is intact regardless. Higher lows from 575 to roughly 2,000 and higher highs from 1,250 to 2,550. Nothing here is broken — it is simply extended. FUNDAMENTAL BACKDROP — THE TURNAROUND IS REAL AND CASH-BACKED Sales .............. 16,405 (FY22) > 27,958 (FY26) > 29,967 (TTM) Operating profit ... 219 (FY22) > 8,160 (FY26) > 9,538 (TTM) OPM ................ 1.3% > 10% > 19% > 23% > 29% > 32% (TTM) Net profit ......... -1,528 (FY22) > 5,355 (FY26) > 5,551 (TTM) EPS ................ -33.62 (FY22) > 116.65 (FY26) > 120.98 (TTM) Sales CAGR ......... 3-year 19%, TTM 28% — accelerating Profit CAGR ........ 3-year 140%, TTM 61% ROE ................ 13% (5yr) > 22% (3yr) > 29% (last year) ROIC ............... 24% Piotroski F-score .. 7 of 9 Debt / equity ...... 0.30 — moderate and manageable Dividend ........... 0.78% yield, 15% payout Critically, the cash flow confirms it rather than contradicting it: CFO ................ 367 (FY22) > 1,897 > 3,648 > 3,000 > 7,334 (FY26) CFO / OP ........... 105% in FY26 — earnings are converting to cash Free cash flow ..... 5,527 Cr in FY26, up from 1,347 Cr Capex .............. 4,172 and 3,865 Cr in FY25-26 — reinvesting heavily Many turnarounds show accounting profit without cash. This one does not. A 105% cash conversion rate alongside record FCF is what separates a genuine operational recovery from a presentation. THE VALUATION ARGUMENT — AND THE COUNTER-ARGUMENT Lupin's TTM P/E has compressed from roughly 110 to about 19.6 over five years — its lowest reading in that window and roughly half its own five-year median of 37.0. The stock has risen substantially and become cheaper doing it, because earnings grew faster than price. That is an unusual and genuinely bullish configuration. The counter sits in the same data. Forward P/E of 21.03 is HIGHER than the trailing 19.58, meaning consensus models a modest earnings decline. The likely reason is the margin itself: a 32% operating margin is exceptional for a generics-weighted pharmaceutical business where peers typically run 20-25%. Margins like that usually come from limited-competition or exclusivity-window products, and those windows close. Three scenarios worth holding in mind: - Re-rating: EPS holds near 120 and the multiple moves toward the 30s. Implies a substantially higher price. - Base case: mild normalisation, EPS in the low 100s at 22x. Roughly current levels. - Reversion: margins retrace toward the mid-20s, EPS toward the 80s at 18x. Implies the 1,500s. The spread between those outcomes is wide, and it is exactly why entering at the 2,000-2,120 band rather than at 2,363 matters. Verify what is driving the margin surge and how durable it is. That single question determines which scenario applies. THE SHAREHOLDING SIGNAL Promoters ......... 46.85%, essentially unchanged for a decade. No dilution, no drift. FIIs .............. 13.32% (Mar 2023) rising to 22.42% (Jun 2026) — nine points added DIIs .............. 28.92% (Mar 2023) falling to 24.65% — domestic funds trimming Public ............ 10.39% falling to 6.08% — retail float collapsing Shareholders ...... roughly 3.0 lakh, broadly stable The clean read: foreign institutions have been the marginal buyer throughout the entire re-rating, absorbing both domestic institutional trimming and retail exit. Promoters have not sold a share. Public float at 6.08% with institutions and promoters holding roughly 94% between them means very little stock is genuinely available — supportive on the way up, and thin on the way down. FUTURE PLANS — WHAT THE COMPANY IS BUILDING (Framework as of my information; verify against the latest annual report, investor presentation and exchange filings.) - Complex generics and inhalation. Respiratory and inhalation products are Lupin's differentiated capability. These are hard to manufacture, hard to get approved, and therefore carry margins that plain oral solids do not. This is the structural reason margins can stay above peer levels. - Biosimilars. A longer-dated, capital-intensive optionality with meaningful upside if approvals land in regulated markets. - US specialty and branded assets. Reducing dependence on price-eroding commodity generics. - India branded formulations. A steady, growing, rupee-denominated base that offsets US volatility. - Reinvestment. Capex near 3,900-4,200 Cr per year against 5,527 Cr of FCF means growth is being funded internally rather than by leverage. The strategic read: Lupin is trying to convert a cyclical exclusivity windfall into a structurally higher-margin portfolio. Whether that conversion completes before current high-margin products erode is the entire investment question. COMPETITIVE LANDSCAPE Lupin sits mid-pack by size among Indian pharma majors — behind Sun Pharma, and competing directly with Dr Reddy's, Cipla, Zydus, Aurobindo and Torrent. In the US generics channel it also faces global players including Teva, Sandoz, Viatris and Amneal. Where Lupin competes well: inhalation and complex generics, where approval barriers limit the number of entrants and pricing holds far better than in commodity orals. Its US respiratory franchise is the reason a 32% margin is even conceivable. Where it is exposed: the commodity generics book, where price erosion is relentless and scale favours larger competitors. And unlike Sun Pharma, Lupin has less of a high-margin specialty branded business to cushion generic deflation. The peer-relative point worth making: at roughly 19.6x trailing with 29% ROE and 24% ROIC, Lupin does not screen expensive against Indian pharma peers, most of which trade at higher multiples on lower returns. The market appears to be discounting the durability of the earnings rather than the quality of the business. MACRO LENS - US generic price erosion. The structural headwind for the entire Indian pharma sector — mid-single-digit annual deflation is the norm. Complex generics resist it; commodity products do not. This is the single most important macro variable for Lupin. - US FDA compliance. Binary and unhedgeable. A warning letter or import alert on a key facility can remove a product line overnight. Lupin has lived through exactly this, and it was a primary cause of the 2017-2022 collapse. - Pharmaceutical tariffs and trade policy. US measures targeting imported pharmaceuticals are a live policy risk for Indian exporters and would hit margins directly. - Currency. Substantial USD revenue against a rupee cost base makes Lupin a structural beneficiary of rupee weakness — a genuine tailwind that operates independent of volumes. - India domestic market. Steady high-single-digit growth in branded formulations provides a defensive, non-dollar earnings base. - API supply chain. Concentration of active ingredient sourcing in China is a persistent input and geopolitical risk for all Indian formulators. - Indian largecap flows. At Rs 1.08 lakh crore this is an index-relevant name; domestic and foreign allocation shifts move it regardless of fundamentals. INVALIDATION A decisive weekly close below 1,980 breaks the reclaimed 2015 band and ends the structural thesis. A nine-year ceiling failing after a successful retest would be a serious signal, not a routine pullback. Softer warning: repeated rejections at 2,440-2,550 while price drifts back toward the band means the breakout is stalling and the margin normalisation debate is being resolved the wrong way. RISKS WORTH NAMING - Margin durability is the whole thesis. A 32% OPM is well above sector norms. If it is exclusivity-driven, it is temporary by definition. Forward estimates already hint at this. - Forward P/E above trailing. The market is modelling an earnings dip, not growth. That caps multiple expansion until estimates turn up. - Regulatory binary risk. FDA action on a key plant is the classic Indian pharma tail risk and this company has suffered it before. - Rising interest cost. Interest expense has climbed from 143 Cr (FY22) to 452 Cr (TTM) even as profits soared. Worth understanding why. - Other income volatility. FY26 included 523 Cr of other income against -82 Cr TTM. Look through non-operating items when assessing the earnings trend. - Thin public float. Only 6.08% in public hands amplifies moves in both directions. - Extended location. Near all-time highs after a 4x from the 2022 low. Excellent businesses still make poor entries. TRADE PLAN Value entry ........ 2,120 – 2,200 on a weekly hold with volume Momentum entry ..... Weekly close above 2,550 into blue sky Invalidation ....... Weekly close below 1,980 Target 1 ........... 2,550 (all-time high) Target 2 ........... 2,880 – 2,950 (measured move above the 2,440 shelf) Geometry ........... Worse than 1:1 from 2,363. Roughly 3:1 from 2,120. Wait for the level Sizing ............. Regulatory tail risk is real. Size for a gap, not for a drawdown Not chasing 2,363 into a weekly rejection. This is the strongest business on my watchlist and still the wrong price. The band is where the trade lives, and if it never comes back, the breakout above 2,550 is the alternative. The single thing to monitor: whether operating margin holds above the high 20s in coming quarters. That answers the only question that matters here. Not financial advice — my own chart and filings interpretation, shared for discussion. Figures are read from public data panels; verify against the company's filings before acting. Do your own research and manage your own risk.